ASKA Pharmaceutical saw the highest growth of 99% in patent filings and 99% in grants in October in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 99% and grants by 99%. GlobalData’s DataBook provides a comprehensive analysis of ASKA Pharmaceutical’s patent filings and grants. Buy the databook here.
ASKA Pharmaceutical has been focused on protecting inventions in European Patent Office(EPO) with three publications in Q4 2023
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 50% filings and 100% grants. The European Patent Office(EPO), and South Korea(KR) patent Office are among the top ten patent offices where ASKA Pharmaceutical is filings its patents. Among the top granted patent authorities, ASKA Pharmaceutical has 100% of its grants in European Patent Office(EPO)
Johnson & Johnson and Pfizer could be the strongest competitors for ASKA Pharmaceutical
Dysuria related patents lead ASKA Pharmaceutical portfolio followed by intermittency of urination
ASKA Pharmaceutical has highest number of patents in dysuria followed by intermittency of urination.
For comprehensive analysis of ASKA Pharmaceutical's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.